Biosynthetic Technologies appointed Matthew Kriech CEO. He previously served as the company’s chief operating officer, before being named president last year. Kriech played roles in commercialization of Biosynthetic’s Estolides technology, the development of its supply chain and the 2021 acquisition of Innoleo, which became Biosynthetic’s commodity oleochemical arm.